Efficacy and safety of gsk3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: a phase iia randomized, multicenter, double-blind, sponsor-open, comparative trial

HIGHLIGHTS

• who: Chika Akinseye and collaborators from the Modelling and Simulation, GSK, Stevenage, Hertfordshire, United Kingdom have published the paper: Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial, in the Journal: PLOS ONE of 23/08/2022
• what: Lack of clinical benefits with GSK3772847 was likely due to the small sample size, highlighting the need for larger prospective studies.

SUMMARY

Current treatments for allergic fungal airway disease are not specific for asthma . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.